Injection frequency plays a large role in visual acuity outcomes. However, there does seem to be a ceiling effect at 10 injections, says David F. Williams, MD. Why is this?
A novel light-activated technology may be the first targeted therapy developed for the most common primary cancer of the eye, says Amy C. Schefler, MD.
Calvin Mein, MD, explains why intraocular injection of C3F8 gas alone with limited face-down positioning appears to be a viable alternative for treatment of symptomatic VMT and small stage-2 macular holes.
This is a post-only, outbound email. Please do not reply to this email as we will be unable to respond to your reply. Please use the links provided if you have questions or concerns regarding this email or your subscription.
This email was sent by: %%Member_Busname%% %%Member_Addr%% %%Member_City%%, %%Member_State%%, %%Member_PostalCode%%, %%Member_Country%%
